Principal Financial Group Inc. Has $8.35 Million Stake in Acorda Therapeutics, Inc. (ACOR)
Principal Financial Group Inc. decreased its holdings in shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 353,171 shares of the biopharmaceutical company’s stock after selling 3,082 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Acorda Therapeutics worth $8,352,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Piedmont Investment Advisors LLC bought a new position in Acorda Therapeutics during the 2nd quarter worth approximately $199,000. Municipal Employees Retirement System of Michigan boosted its stake in Acorda Therapeutics by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 410 shares during the last quarter. Laurion Capital Management LP bought a new position in Acorda Therapeutics during the 2nd quarter worth approximately $219,000. Crossmark Global Holdings Inc. bought a new position in Acorda Therapeutics during the 3rd quarter worth approximately $233,000. Finally, Aperio Group LLC boosted its stake in Acorda Therapeutics by 2.7% during the 2nd quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 343 shares during the last quarter.
Acorda Therapeutics, Inc. (NASDAQ ACOR) opened at $20.45 on Wednesday. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49. Acorda Therapeutics, Inc. has a one year low of $13.60 and a one year high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). The business had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) EPS. equities analysts forecast that Acorda Therapeutics, Inc. will post -0.07 EPS for the current year.
Several research firms recently weighed in on ACOR. Piper Jaffray Companies reissued a “neutral” rating and set a $22.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, November 28th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research note on Thursday, September 28th. BidaskClub raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. TheStreet lowered shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research note on Friday, November 17th. Finally, HC Wainwright set a $34.00 price target on shares of Acorda Therapeutics and gave the company a “buy” rating in a research note on Monday, November 20th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $21.47.
In other news, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the sale, the insider now owns 33,150 shares of the company’s stock, valued at $680,569.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.90% of the company’s stock.
Acorda Therapeutics Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics, Inc. (NASDAQ:ACOR).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.